Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review

References

• Qian J, Xu H. COVID-19 disease and dermatomyositis: a mini-review. Front Immunol. 2022;12. doi:10.3389/FIMMU.2021.747116
   Web of Science ®Google Scholar
• Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology. 2014;53(3):397–405. doi:10.1093/rheumatology/ket279
   PubMed Web of Science ®Google Scholar
• Mastaglia F. Inflammatory muscle diseases. Neurol India. 2008;56(3):263–270. doi:10.4103/0028-3886.43444
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–678. doi:10.1002/ana.20464
   PubMed Web of Science ®Google Scholar
• Gokhale Y, Patankar A, Holla U, et al. Dermatomyositis during COVID-19 pandemic (a case series): is there a cause effect relationship? J Assoc Physicians India. 2020;68(11):20–24.
   PubMedGoogle Scholar
• Movahedi N, Ziaee V. COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? Pediatr Rheumatol. 2021;19(1). doi:10.1186/s12969-021-00570-w
   PubMed Web of Science ®Google Scholar
• Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021;23(8). doi:10.1007/s11926-021-01023-9
   PubMed Web of Science ®Google Scholar
• Naveen R, Sundaram TG, Agarwal V, Gupta L. Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic. Rheumatol Int. 2021;41(1):67–76. doi:10.1007/s00296-020-04737-8
   PubMed Web of Science ®Google Scholar
• Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195–3204. doi:10.1007/s10067-020-05334-7
   PubMed Web of Science ®Google Scholar
• Gupta L, Lilleker JB, Agarwal V, Chinoy H, Aggarwal R. COVID-19 and myositis-unique challenges for patients. Rheumatology. 2021;60(2):907–910. doi:10.1093/rheumatology/keaa610
   PubMed Web of Science ®Google Scholar
• Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41(6):1021–1036. doi:10.1007/s00296-021-04819-1
   PubMed Web of Science ®Google Scholar
• Cao M, Zhang S, Chu D, et al. COVID-19 or clinical amyopathic dermatomyositis associated rapidly progressive interstitial lung disease? A case report. BMC Pulm Med. 2020;20(1). doi:10.1186/s12890-020-01335-z
   Web of Science ®Google Scholar
• Hayano S, Tokunaga K, Imamura Y, Oshikawa H. Dermatomyositis-related interstitial lung disease mimicking COVID-19 pneumonia. Cleve Clin J Med. 2021;88(9):484–486. doi:10.3949/CCJM.88A.20204
   PubMed Web of Science ®Google Scholar
• Megremis S, Walker TDJ, He X, et al. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis. 2020;79(10):1383–1386. doi:10.1136/annrheumdis-2020-217522
   PubMed Web of Science ®Google Scholar
• Borges NH, Godoy TM, Kahlow BS. Onset of dermatomyositis in close association with COVID-19 - a first case reported. Rheumatology. 2021;60(SI):SI96. doi:10.1093/rheumatology/keab290
   PubMed Web of Science ®Google Scholar
• Shahidi Dadras M, Rakhshan A, Ahmadzadeh A, et al. Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection: a new potential trigger for musculoskeletal autoimmune disease development. Clin Case Rep. 2021;9(10). doi:10.1002/ccr3.4931
   Web of Science ®Google Scholar
• Balaini N, Varshney M, Goel A, Lal V, Shree R. Dermatomyositis with superimposed COVID-19 myositis. J Neurol Sci. 2021;429:118355. doi:10.1016/j.jns.2021.118355
   Web of Science ®Google Scholar
• Ho BVK, Seger EW, Kollmann K, Rajpara A. Dermatomyositis in a COVID-19 positive patient. JAAD Case Rep. 2021;13:97–99. doi:10.1016/j.jdcr.2021.04.036
   PubMedGoogle Scholar
• Sacchi MC, Tamiazzo S, Lauritano EC, Bonometti R. Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis? Eur Rev Med Pharmacol Sci. 2020;24(22):11960–11963. doi:10.26355/eurrev_202011_23857
   PubMed Web of Science ®Google Scholar
• Lee AYS, Lee C, Brown DA, Suan D. Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination. Postgrad Med J. 2022;postgradmedj-2022–141510. doi:10.1136/POSTGRADMEDJ-2022-141510
   Web of Science ®Google Scholar
• Gouda W, Albasri A, Alsaqabi F, Al sabah HY, Alkandari M, Abdelnaby H. Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. J Korean Med Sci. 2022;37(5). doi:10.3346/JKMS.2022.37.E32
   PubMed Web of Science ®Google Scholar
• Derbel A, Guermazi M, El Moctar EM, et al. Dermatomyositis following COVID-19 infection. La Revue de Médecine Interne. 2021;42:A445. doi:10.1016/j.revmed.2021.10.186
   Google Scholar
• Okogbaa J, Batiste L. Dermatomyositis: an acute flare and current treatments. Clin Med Insights Case Rep. 2019;12. doi:10.1177/1179547619855370
   PubMed Web of Science ®Google Scholar
• Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–340. doi:10.1136/annrheumdis-2016-209247
   PubMed Web of Science ®Google Scholar
• Vastert S, Dolezalova P, Feldman B, et al.SHARE-workpackage 5: development of best practices of diagnosis and treatment for paediatric rheumatic diseases throughout Europe. Pediatr Rheumatol. 2014;12:no pagination.
   Google Scholar
• Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10(12):3592. doi:10.3390/CELLS10123592
   PubMed Web of Science ®Google Scholar